PCRX Pacira BioSciences Corporate Presentation November 2023 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Secu ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' pres ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other Jurisd ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Rohit Bhasin - Needham & Company Boris Peaker - TD Cowen Operator Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call. At this t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other Juris ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - CEO Ron Ellis - Chief Strategy Officer Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Greg Fraser - Truist Securities Rohit Bhasin - Needham & Co Operator Good day, and thank you for standing by. Welcome to the Q1 2023 Pacira BioSciences Inc Earnings Confere ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Oren Livnat - H.C. Wainwright Andreas Argyrides - Wedbush Greg Fraser - Truist Securities Operator Go ...

• Ex-U.S. market expansion in 2023 • Significant upside in current and new markets 7 EXPAREL Penetration Market Procedures Orthopedics General Surgery Women's Health Cardiothoracic OMFS 18M 1M 3M 6M ~34M 6M Potential Procedures1 slowdown in growth in 2022 %YoY Growth (Moving Annual Total) 2020 vs 2021 2021 vs 2022 2021 2022 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 35 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 W44 W26 YE W26 W44 MAT YoY recovery from 2020 lockdo ...